IPO News | Sugar Kee Healthcare Submits Another Listing to the Hong Kong Stock Exchange

The Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on August 28, Hangzhou Tangji Medical Technology Co., Ltd. (abbreviation: Tangji Medical) submitted a listing application to the main board of the Hong Kong Stock Exchange, with ICBC International and Caitong International as co-sponsors. According to the prospectus, Tangji Medical is a medical device company headquartered in China that focuses on providing innovative solutions for the treatment and comprehensive management of metabolic diseases. As of the last practical date, the company had (i) a core product, the gastric transit stent system (GBS), a digestive endoscopic duodenal-jejunal bypass cannula (DJBL) device for obesity, and the company is expanding the approved indications for GBS for lower BMI; (ii) two other products and a digital health management platform that we have approved for registration; and (iii) 13 other pipeline products.